Skip to main content
CND In the News

Rhode Island Man Grateful for Syn-One Test® in Aiding the Diagnosis of Parkinson’s Disease

By April 12, 2023April 18th, 2023No Comments

Rhode Island Man Grateful for Syn-One Test® in Aiding the Diagnosis of Parkinson’s Disease

WJAR news reported last month about a Pawtucket, Rhode Island man, Roger Miller, who began to suffer from shaky movements about 10 years ago. Neurologist Dr. Motasem Al-Yacoub says that as those movements evolved into tremors over time, he initially believed that Miller had essential tremor.

But with no reliable tests available to help confirm the diagnosis, Al-Yacoub’s best option was to prescribe medication for essential tremor to see if it helped. However, Miller’s symptoms didn’t improve.

Then Al-Yacoub heard about the Syn-One Test from CND Life Sciences and asked Miller if he’d like to try it. A month after sending Miller’s three small skin biopsies to CND’s lab in Scottsdale, Arizona, Miller and Al-Yacoub had an answer.

“I know it sounds funny, but I’m happy to know I got Parkinson’s,” said Miller. “…that helped us a lot in addressing his tremors the right way, giving him the right treatment and the right dosing,” added Al-Yacoub.

Read the story

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.